Archive | July, 2017

Must See Video—CEOs explain sourcing Family Offices, Working Your Pipeline and Cost of Campaigns – Tales from the Road at RESI

13 Jul

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

More frequently than not LSN captures content through its RESI panels that hits the nail on the head. The recent “Tales from the Road” Panel does just that. It’s 6 minutes long but worth a viewing it if you are a scientist-entrepreneur or fundraising CEO. The most vital take-aways include how to source potential investors (particularly family offices), the process of “working” your pipeline of investors, and the costs associated with conducting a successful campaign.

The panel brought together successful biotech and medtech entrepreneurs to tell their stories of successfully raising capital. These are seasoned entrepreneurs who have been there done that and collectively have raised numerous private financing rounds and have exited multiple companies, with combined total deals exceeding $750 MM. They came to RESI San Diego to share their wisdom to fellow fundraising executives and provide insight in order to help their peers succeed.

Tags: , , , , ,

RESI Premier Partnering Plus – An In Depth Look At RESI’s New Enhanced Partnering Service

13 Jul

By Natasha Eldridge, RESI Conference Manager, LSN

natasha-wp-new

In last week’s Next Phase newsletter, LSN announced the new Premier Partnering Plus service for RESI attendees.  This week, we’d like to give you a more in depth look at how Premier Partnering Plus will take RESI Partnering to the next level, and show you an example of the extra information that will be available to attendees who opt for the Premier Partnering Plus pass.  RESI Early Bird rates end on Friday, so now is the time to sign up.

Premier Partnering Plus users will receive:

  • Detailed investment and deal mandate information to help dial in who they need to meet with based on fit
  • Include specifics on the sectors and subsectors
  • Indication interest, company and management team requirements
  • Contact information and best way to reach out to an investor

Below, you can take a look at an example of what Premier Partnering Plus attendees will be able to see once RESI Partnering launches.

This a first for integrating a world class investor & strategic data platform with a partnering application, and will make attendees who use the service much more selective, efficient and successful in their partnering activities.

(Click to watch LSN Investor Platform intro video)

Tags: , ,

Calling All Life Science Entrepreneurs – Enter the RESI Boston Innovation Challenge

13 Jul

By Chris Cummings, Senior Business Development Manager, LSN

Christine A. Wu, Senior Research Analyst, LSN

chrsitineRESI is coming home to Boston and so is the RESI Innovation Challenge. This September’s life science innovation competition will showcase the most promising new health technologies in the RESI Innovation Challenge. If you are fundraising and aim to build a presence in the Boston’s booming healthcare scene, we’d like to see your application.

The RESI Innovation Challenge invites the top-tier early-stage companies in therapeutics, medical devices, diagnostics and healthcare IT to present from around the globe. All applicants will be vetted on the crucial balance of the quality of the company’s scientific innovation and the investment potential based on the company current standings and management team.

On September 26th, RESI’s estimated 1000 attendees will receive “RESI Cash” to “invest” in the company whom they believe to be the most “investible” of the contestants. The top three winners with the most RESI cash will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership.

In the past we have seen around 50% of Innovation Challenge companies receive funding within a year from their exhibition at RESI. Be sure not to miss out on the chance of adding to this statistic – apply for the Innovation Challenge.

See below for the previous RESI Innovation Challenge testimonials.

“RESI Innovation Challenge was a fantastic way for us to increase exposure to investors attending the event. We highly recommend leveraging the Innovation Challenge with the one-on-one partnering platform to get more face time with investors.”

– Herman Lo, CEO, ViewsIQ Inc.

3rd Place in San Diego IC

DSC00392

“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
– Raymond Shih, President, Co-Founder, QoC Health
3rd Place, RESI on MaRS, June 23, 2016

02

“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

Tags: , , , ,

Hot Investor Mandate 1: Private Equity Firm Seeks Commercial-Stage Life Science and Healthtech Opportunities

13 Jul

A private equity firm based in Philadelphia, PA provides expansion and growth capital to commercial-stage companies in select healthcare sectors. The firm recently closed its first fund in June of 2016 at $200M, and is targeting initial equity investments around $10M with up to another $5M-$10M in additional capital reserved for follow-on investments. The partners of the firm have significant experience investing in and building healthcare companies, and look to leverage their operational experience to help portfolio companies grow and scale. The firm is focused on US-based companies, and prefers to lead rounds but will also participate as a minority investor in a syndicate. The firm is targeting 3-4 investments per year.

The firm is focused on commercial-stage companies within specialty pharmaceutical, medical technology, healthcare services and digital health that are generating at least $5M in revenue. It is not a requirement that the company have positive EBITDA, but should be anticipating positive cash flow within 18 months. 1315 Capital has particular interest in obesity prevention, opioid addiction, podiatry and cosmeceuticals.

The firm prefers to work with experienced management teams and typically avoids first time entrepreneurs, but will evaluate companies with a great product and complete management team. The firm prefers to work with companies that have more than one product. The firm does seek a board seat along with investment and prefers to be involved with the management team, given the firm’s expertise in operations and ability to directly help the company scale.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Corporate VC Invests Strategically in Healthcare Materials Science and Nutrition

13 Jul

The corporate venture capital arm of a global science-based company active in health, nutrition and materials makes equity investments into seed and venture stage companies, generally taking less than 25% ownership. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Isreal.

The firm is looking for materials science companies in orthopedics, soft tissue repair and drug delivery. The firm also actively invests in human nutritional health and advanced materials for solar energy . While the firm has invested in companies all the way from seed to PIPE, they generally invest into companies that have products in development or early stage commercialization.

The firm highly values experience in a firms management team and generally looks to take a board seat and play an active role in its portfolio companies. The firm is looking for companies that are interested in cooperation/alignment with the parent company’s relevant businesses.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Asia-Based Pharma Opens US Office to Make Early Stage Equity Investments in Novel Platform Technologies

13 Jul

A pharmaceutical enterprise headquartered in Beijing, China has set up a biotech subsidiary in the USA and is actively seeking cutting-edge life science technologies around the world. The firm makes equity investments of US$2-10 million in Seed to Series B stage companies, while later stages up to pre-IPO may also be considered. For overseas deals, the firm prefers to co-invest with top-tier lead investors. The firm is looking for opportunities across the globe.

The firm is looking for technologies that are a strategic fit with its portfolio across biopharmaceuticals, medical devices, healthcare IT and healthcare services. The firm is most interested in innovative platform technology in small molecule or biologic therapeutics targeting large markets in China, including aging population, oncology, diabetes, women and children’s health. The firm considers early-stage companies from seed to Series B.

The firm seeks experienced management teams backed by strong, reputable VC firms. The firm typically requests board representation post-investment. The firm prefers to retain China rights, but this is not a requirement for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Global Diagnostics Firm Looks For Early Stage Partners in Point of Care, Molecular and Tissue Diagnostics

13 Jul

A global diagnostics firm headquartered in Europe is conducting global business development and licensing searches in all stages of clinical diagnostics research and development, regardless of the technology involved. The firm employs a variety of deal structures including IP rights in- and out- licensing, product or technology co-development,  and M&A.

The firm is interested in new technologies in point of care diagnostics, molecular diagnostics, tissue diagnostics, bioinformatics, and instrumentation, sequencing and associated software. The firm’s indications of interest include oncology, sepsis, pre-natal health and women’s health, bone metabolism, cardiovascular disease, diabetes and metabolic disease, kidney disease, infectious disease, and genetic disorders.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

← Older Entries
Newer Entries →